A coronavirus vaccine (COVID 19) is being developed by AdaptVac (joint-venture between ExpreS2ion Biotechnologies and NextGen Vaccines, a spin-out of the University of Copenhagen) for prevention against COVID-2019 infections caused by the SARS-CoV-2 virus. The company is using its universal viral Capsid-Like Particle (CLP) technology to develop the COVID 19 candidate. The protein based CLP approach, activates the immune system in a potentially synergistic manner. Early research is underway in Denmark.
AdaptVac's viral capsid-like particle technology enables quick adaptation of the vaccine to viral mutations. The company utilises the split-protein conjugation system to generate stable isopeptide bound antigen-virus -like particle (VLP) complexes by simply mixing of the antigen and VLP components.
AdaptVac is actively seeking partners for the development of the coronavirus vaccine (AdaptVac pipeline, March 2020).
AdaptVac is a joint venture between ExpreS2 ion Biotechnologies and NextGen Vaccines, combining ExpreS2 ion’s platform with novel proprietary and ground-breaking viral capsid-like particle (CLP) technology developed at the University of Copenhagen.
In May 2020, Bavarian Nordic entered into an exclusive agreement with AdaptVac to license AdaptVac’s proprietary capsid virus like particle (VLP) based SARS-CoV-2 subunit vaccine. Both the parties seek to enter into the final license agreement within the next two months. Upon execution of a final license agreement, Bavarian Nordic will make an initial upfront payment to Adaptvac in addition to future development and sales milestones and royalties. 
In April 2020, AdaptVac and AGC Biologics entered into the manufacturing agreement for manufacture and scale-up of the COVID-19 (SARS-CoV-2) coronavirus vaccine. This agreement leverages AGC Biologics global manufacture expertise to accelerate the development and GMP manufacture of the SARS-CoV-2 capsid-Virus Like Particle (cVLP) vaccine.
Key Development Milestones
In March 2020, AdaptVac received an Horizon 2020 EU grant of €2.7million as part of the PREVENT-nCoV consortium. The company intends to use the funds for development of the coronavirus vaccine as well as to support production of the needed clinical supply of viral capsid-like particles for clinical projects, including AV 001 [see Adis Insight Drug Profile800052950]   .
In January 2020, AdaptVac was granted a US patent number 10 526 376 B2 “Virus-like particle with efficient epitope display" covering its viral capsid-like particle (CLP) technology platform, and any vaccine produced using it (including the Her2 immunotherapy, AV 001 [see Adis Insight Drug Profile 800052950]. The new patent expands AdaptVac’s protection, thereby covering the entire pipeline of vaccines and immunotherapies including the heart disease therapy, targeting cholesterol reduction, as well as a long list of viral, bacterial, and additional chronic disease vaccines. The patent is valid until 2036  .
The University Of Copenhagen has pending patent applications CA 3 010 975 A1, EP 3 244 915 A1, EA 201 791 598 A8, WO 2016 112 921 A1 and AU 2016 207 099 A1, DE 16 703 049 T1 entitled "Virus like particle with efficient epitope display", covering its virus-like particle (VLP) based vaccine. The patent relates to a technology and method for making a virus-like particle based vaccine with efficient epitope display and capable of inducing a strong and long-term protective immune response. The patent is related to the use of VLP-based vaccine for the prophylaxis and/or treatment of a diseases including, but not limited to, cancer, cardiovascular, infectious, chronic, neurological, asthma, allergy, immune-inflammatory diseases or disorders  .